News & Events

December 2, 2019

BrainsWay Announces Successful Results in Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as an Aid in Smoking Cessation

Primary and secondary endpoint achieved with statistical significance. Company intends to meet with...

November 25, 2019

BrainsWay Reports Third Quarter 2019 Financial Results and Operational Highlights

Third quarter revenues were $5.9 million, up 38% over the same quarter in the prior year

November 25, 2019

BrainsWay Appoints Medical Technology Industry Leader Christopher R. von Jako, Ph.D., as President and Chief Executive Officer

JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its...

November 25, 2019

BrainsWay‘s New Stimulator for Deep Transcranial Magnetic Stimulation Makes German Debut at the 2019 German Association for Psychiatry, Psychotherapy and Psychosomatics Congress

JERUSALEM, Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced...

October 1, 2019

BrainsWay Announces Innovative Deep Transcranial Magnetic Stimulation System Showcase Presentation at this Year’s Psych Congress Meeting

JERUSALEM, Oct. 01, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced...

September 19, 2019

BrainsWay Announces Further Leadership Transition to U.S.

Company Intends to Appoint U.S.-Based CEO

August 26, 2019

BrainsWay Reports Second Quarter 2019 Financial Results and Operational Highlights

Company also announces changes to U.S. Management Team

July 18, 2019

Groundbreaking Study Demonstrates Advantages of BrainsWay Deep TMS in Treating Major Depressive Disorder

First head-to-head, randomized controlled trial of its kind comparing Deep TMS, TMS and medication in...

June 27, 2019

New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay’s Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder

First non-invasive device for OCD achieves 45% response rate among patients after one month follow up,...

June 24, 2019

BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder

Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites...

June 13, 2019

BrainsWay To Present At The 2019 Raymond James Life Sciences And MedTech Conference

JERUSALEM and HACKENSACK, N.J., June 13, 2019 – BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay”...

May 22, 2019

BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment

More than 260 participants have been enrolled to the study

March 5, 2019

BrainsWay Announces New Clinical Support Program for Physicians Treating Obsessive-Compulsive Disorder: – “BrainsWay OCD Launchpad to Success”

Program supports physicians in successfully implementing OCD Deep TMS treatment, through in-depth clinical...

March 4, 2019

BrainsWay Expands Intellectual Property Position by Obtaining Rights to Multi-Channel Transcranial Magnetic Stimulation Patent Portfolio

Acquires Multi-Channel TMS Patent Portfolio from TMS Innovations. Enters into an Exclusive Option Agreement...

February 20, 2019

BrainsWay Expands its Deep TMS Commercial Footprint into Asia Pacific

Enters into an Agreement to Distribute its Deep Transcranial Magnetic Stimulation System in South Korea.

January 29, 2019

BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder

Approval allows BrainsWay’s Deep TMS System to be marketed throughout Japan.

October 17, 2018

BrainsWay to Showcase Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at the 2018 Annual Psych Congress

Showcase represents the public debut of BrainsWay’s Deep TMS system for OCD Healthcare providers will...

June 7, 2018

BrainsWay and Cohen Veterans Bioscience Announce Biomarker Research Collaboration in Post Traumatic Stress Disorder

Unique Biomarkers Sought to Enable Personalized Medicine Approach for Treatment of Post Traumatic Stress...

Find a provider near you or contact us today.

Find a Provider Contact Us